Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Onyx Pharmaceuticals

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Friday, Jefferies & Company reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX), and raised its price target from $101.00 to $103.00.

Jefferies noted, “ONXX reported a strong Kyprolis U.S. sales launch w/ $19M in only 8 wks into the launch (v. JEF: $3M), citing contributing factors such as pre-identification of pts prior to launch, and Kyprolis as the first tx in the salvage setting serving an unmet medical need. As a result we have adjusted our 2012-2013 Kyprolis revenues and raised our PT to $103 from $101, and reiterate our Buy.”

Onyx Pharmaceuticals closed on Thursday at $80.33.

Latest Ratings for ONXX

Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (ONXX)

View Comments and Join the Discussion!

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Life Technologies

UPDATE: KeyBanc Capital Markets Downgrades McGrath RentCorp on Lack of Visibility